PubMed İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://acikerisim2.beykoz.edu.tr/handle/20.500.12879/5

Browse

Now showing 1 - 3 of 3

De Novo Malignancy Development Following Kidney Transplantation: Managing Risks and Outcomes in Clinical Practice
(Galenos Publ House, 2025) Huseynov, Amil; Cicek, Sevim Nuran Kuslu
Objective: Denovo malignancy is a significant complication following kidney transplantation, attributed to prolonged immunosuppression.This study evaluates the incidence, risk factors, and clinical outcomes of denovo malignancies in kidney transplant recipients. Material and Methods: A retrospective cohort analysis was conducted on 1200 kidney transplant recipients between 2016 and 2023. Patients were categorized based on the presence or absence of de novo malignancies. Statistical analyses were performed to identify risk factors, including age, sex, comorbidities, and immunosuppressive regimens. Patient and graft survival were assessed using Kaplan-Meier analysis and the log-rank test. Results: Among the study population, 43 patients (3.6%) developed de novo malignancies. The most frequent malignancy types were non-melanoma skin cancers (27.9%) and post-transplant lymphoproliferative disorders (18.6%). Patients with malignancies exhibited a lower three-year survival rate (83.7%) compared to those without malignancies (91.4%), though the difference was not statistically significant (p=0.067). Graft survival at three years was slightly lower in the malignancy group (84.0% vs. 88.7%, p=0.146). Older recipient age was identified as a significant risk factor (hazard ratio=1.03 per year, p=0.025). Conclusion: De novo malignancy remains a concern in kidney transplant recipients, particularly among older patients. Regular screening protocols, lifestyle interventions, and individualized immunosuppressive regimens are essential to mitigate risk and improve outcomes.
Predictive Impact of PI-RADS 3 Lesion Volume/Total Prostate Volume Ratio in Prostate Cancer Diagnosis in Biopsy-Naïve Patients
(TÜBİTAK Scientific & Technological Research Council Turkey, 2025) Tokuç, Emre; Kayar, Rıdvan; Öztürk, Metin; Kutluhan, Musab Ali; Ozsoy, Emrah; Demir, Samet; Meric, Kaan
Background/aim: To assess the potential of the ratio between PI-RADS 3 lesion volume and total prostate volume as a predictive parameter for guiding the decision to perform a biopsy in patients presenting with PI-RADS 3 lesions on multiparametric prostate magnetic resonance imaging (mpMRI). Materials and methods: A total of 749 patients who underwent mpMRI due to suspected prostate cancer between January 2014 and August 2023 were scanned. Based on predefined inclusion and exclusion criteria, 308 patients were included. Age, total prostate-specific antigen (PSA) value, prostate volume measured in mpMRI, mpMRI result, PI-RADS 3 lesion volume, and biopsy results were collected. The PI-RADS 3 ratio was calculated as PI-RADS 3 lesion volume/total prostate volume. PSA density (dPSA) was calculated. The patients were categorized according to their biopsy results as benign or malignant (subclassified by Gleason group grade), and the two groups were compared. Results: The average PI-RADS 3 ratio was 0.032 ± 0.002. There were 230 (74.7%) patients in the benign group and 78 (25.3%) patients in the malignant group. There was a statistically significant difference detected in average prostate volumes (p < 0.001), dPSA values (p = 0.001), and PI-RADS 3 ratios (p < 0.001). The receiver operating curve analysis of PI-RADS 3 ratio indicated an area under the curve of 0.643 ± 0.037. The optimal cut-off point was 0.026 with a sensitivity of 58.97% and a specificity of 66.96%. A positive, albeit weak, statistically significant relationship was found between PIRADS-3 ratios and dPSA values (rs ρ = 0.261 and p < 0.001). Conclusion: PI-RADS 3 ratio may serve as an auxiliary clinical parameter alongside age, dPSA, and lesion volume alone in identifying more refined candidates for biopsy in the goal of patient care individualization.
Where Can Urodynamic Testing Help Assess Male Lower Urinary Tract Symptoms
(AVES, 2019) Gurbuz, Cenk; Drake, Marcus J.
Urodynamic studies assess the function of the bladder and bladder outlet. They are often useful in the assessment and diagnosis of patients presenting with lower urinary tract symptoms (LUTS). The evidence regarding the value and risks of invasive urodynamics remains insufficient. However, men with LUTS who are assessed by invasive urodynamics are more likely to have their management changed and less likely to undergo surgery. This review discusses the role of urodynamic diagnosis and application in the diagnosis and treatment of male LUTS.

Browse

Browsing PubMed İndeksli Yayınlar Koleksiyonu by Publication Index "TR-Dizin"